-
公开(公告)号：EP3359541B1
公开(公告)日：2020-08-05
申请号：EP16788232.3
申请日：2016-10-07
发明人： AKKARI, Rhalid , ALVEY, Luke Jonathan , BOCK, Xavier Marie , BROWN, Brian S. , CLAES, Pieter Isabelle Roger , COWART, Marlon D. , DE LEMOS, Elsa , DESROY, Nicolas , DUTHION, Béranger , GFESSER, Gregory A. , GOSMINI, Romain Luc Marie , HOUSSEMAN, Christopher Gaëtan , JANSEN, Koen Karel , JI, Jianguo , KYM, Philip R. , LEFRANCOIS, Jean-Michel , MAMMOLITI, Oscar , MENET, Christel Jeanne Marie , MERAYO, Nuria Merayo , NEWSOME, Gregory John Robert , PALISSE, Adeline Marie Elise , PATEL, Sachin V. , PIZZONERO, Mathieu Rafaël , SHRESTHA, Anurupa , SWIFT, Elizabeth C. , VAN DER PLAS, Steven Emiel , WANG, Xueqing , DE BLIECK, Ann
IPC分类号： C07D471/04 , A61K31/437 , A61P11/12 , C07D519/00
-
公开(公告)号：EP3359539A1
公开(公告)日：2018-08-15
申请号：EP16785567.5
申请日：2016-10-07
申请人： AbbVie S.À.R.L. , Galapagos NV
发明人： AKKARI, Rhalid , ALVEY, Luke Jonathan , BOCK, Xavier Marie , CLAES, Pieter Isabelle Roger , COWART, Marlon D. , DE LEMOS, Elsa , DESROY, Nicolas , DUTHION, Béranger , GFESSER, Gregory A. , GOSMINI, Romain Luc Marie , HOUSSEMAN, Christopher Gaëtan , JANSEN, Koen Karel , JI, Jianguo , KYM, Philip R. , LEFRANCOIS, Jean-Michel , MAMMOLITI, Oscar , MENET, Christel Jeanne Marie , NEWSOME, Gregory John Robert , PALISSE, Adeline Marie Elise , PATEL, Sachin V. , PIZZONERO, Mathieu Rafaël , SHRESTHA, Anurupa , SWIFT, Elizabeth C. , VAN DER PLAS, Steven Emiel , WANG, Xueqing
IPC分类号： C07D471/04 , A61K31/437 , A61P11/12 , C07D519/00
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D519/00 , A61K2300/00
摘要： wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
公开(公告)号：EP3359541A1
公开(公告)日：2018-08-15
申请号：EP16788232.3
申请日：2016-10-07
申请人： AbbVie S.À.R.L. , Galapagos NV
发明人： AKKARI, Rhalid , ALVEY, Luke Jonathan , BOCK, Xavier Marie , BROWN, Brian S. , CLAES, Pieter Isabelle Roger , COWART, Marlon D. , DE LEMOS, Elsa , DESROY, Nicolas , DUTHION, Béranger , GFESSER, Gregory A. , GOSMINI, Romain Luc Marie , HOUSSEMAN, Christopher Gaëtan , JANSEN, Koen Karel , JI, Jianguo , KYM, Philip R. , LEFRANCOIS, Jean-Michel , MAMMOLITI, Oscar , MENET, Christel Jeanne Marie , MERAYO, Nuria Merayo , NEWSOME, Gregory John Robert , PALISSE, Adeline Marie Elise , PATEL, Sachin V. , PIZZONERO, Mathieu Rafaël , SHRESTHA, Anurupa , SWIFT, Elizabeth C. , VAN DER PLAS, Steven Emiel , WANG, Xueqing , DE BLIECK, Ann
IPC分类号： C07D471/04 , A61K31/437 , A61P11/12 , C07D519/00
摘要： wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
公开(公告)号：EP3359540A1
公开(公告)日：2018-08-15
申请号：EP16785568.3
申请日：2016-10-07
申请人： AbbVie S.À.R.L. , Galapagos NV
发明人： AKKARI, Rhalid , ALVEY, Luke Jonathan , BOCK, Xavier Marie , BROWN, Brian S. , CLAES, Pieter Isabelle Roger , COWART, Marlon D. , CONRATH, Katja E. , CYR, Douglas , DE LEMOS, Elsa , DE WILDE, Gert Jules Hector , DESROY, Nicolas , DUTHION, Béranger , GFESSER, Gregory A. , GOSMINI, Romain Luc Marie , HOUSSEMAN, Christopher Gaëtan , JANSEN, Koen Karel , JI, Jianguo , KYM, Philip R. , LEFRANCOIS, Jean-Michel , MAMMOLITI, Oscar , MENET, Christel Jeanne Marie , MERAYO, Nuria Merayo , NEWSOME, Gregory John Robert , PALISSE, Adeline Marie Elise , PATEL, Sachin V. , PIZZONERO, Mathieu Rafaël , SHRESTHA, Anurupa , SWIFT, Elizabeth C. , TSE, Chris , VAN DER PLAS, Steven Emiel , WANG, Xueqing
IPC分类号： C07D471/04 , C07D519/00 , A61K31/437 , A61P11/00 , G01N33/68
CPC分类号： A61K31/4545 , A61K45/06 , C07D471/04 , C07D519/00 , G01N33/5023 , G01N2800/382
摘要： A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.
-
5.发明授权NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS 有权新颖的化合物，其药物组合物炎症性疾病的治疗
公开(公告)号：EP3010922B1
公开(公告)日：2017-03-15
申请号：EP14729895.4
申请日：2014-06-12
申请人： Galapagos NV
发明人： DESROY, Nicolas , HECKMANN, Bertrand , BRYS, Reginald Christophe Xavier , JONCOUR, Agnès Marie , PEIXOTO, Christophe , BOCK, Xavier Marie , HOUSSEMAN, Christopher Gaëtan
IPC分类号： C07D487/04 , C07D519/00 , A61K31/4985 , A61K31/5025
CPC分类号： C07D487/04 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/551 , A61K45/06 , C07D519/00
摘要： The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6, R7, R8, W, X, Y, Z, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
-
6.发明公开NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS 有权新颖的化合物，其药物组合物炎症性疾病的治疗
公开(公告)号：EP3010922A1
公开(公告)日：2016-04-27
申请号：EP14729895.4
申请日：2014-06-12
申请人： Galapagos NV
发明人： DESROY, Nicolas , HECKMANN, Bertrand , BRYS, Reginald Christophe Xavier , JONCOUR, Agnès Marie , PEIXOTO, Christophe , BOCK, Xavier Marie , HOUSSEMAN, Christopher Gaëtan
IPC分类号： C07D487/04 , C07D519/00 , A61K31/4985 , A61K31/5025
CPC分类号： C07D487/04 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/551 , A61K45/06 , C07D519/00
摘要： The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6, R7, R8, W, X, Y, Z, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
摘要翻译： 本发明自由圆盘化合物gemäß于式I：其中R 1a，1b中，R2，R4，R5，R6，R7，R8，W，X，Y，Z，Cy和下标a是如所定义。 本发明涉及的化合物抑制汽车塔克（NPP2或ENPP2）它们的生产方法，药物组合物包含相同的，并且使用相同的治疗方法，用于预防和/或治疗的疾病涉及纤维化疾病，增生性疾病，炎症性 疾病，自身免疫性疾病，呼吸系统疾病，心血管疾病，神经变性疾病，皮肤病，和/或异常的血管生成有关的疾病通过施用本发明的化合物。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.03 秒)
